SlideShare a Scribd company logo
Merck KGaA
Darmstadt, Germany
Renaud Jacquemart, Ph.D.
Principal Scientist
Director Vaccines Process Sciences
Enabling the next generation bioprocessing paradigm
High productivity membrane
chromatography
2
The life science business of
Merck KGaA, Darmstadt, Germany
operates as MilliporeSigma
in the U.S. and Canada.
Next Generation Bioprocessing Paradigm
Next Generation
Processing
Any technology, expendable, service, or system which
significantly changes the existing monoclonal
antibody manufacturing template to deliver:
Speed
Flexibility
Quality
Cost4
Performance Drivers
Flexibility
Reduce product change-
over time by 90%
Speed
Reduce facility
construction, mAb
production and product
release times
Cost
90% reduction in cost to
manufacture and capital
expenditure
Quality
Increased robustness
and reliability
BioPhorum Operations Group (BPOG) Technology Roadmap
The Industry Requires Step Change in Performance
Process Analytics
Process
Intensification
Single Use
Enablers
5
Driver Metric Current State 5-yr target 10-yr target
Flexibility
Facility utilization <70% >85% >95%
Product changeover time 3 days <18 hours <8 hours
Time to reconfigure suite
for new process
>2 weeks <1 week <2 days
Speed
Facility build speed 3 years 2 years 1 year
Time to make product 4-6 months 2 months 1 month
Quality
Cost of quality
>10% of operating
cost
10% of operating
cost
2% of operating
cost
Inventory cover 3-6 months 2 months 2 weeks
Cost
Total cost to supply $100/g $50/g $10/g
Cost of facility
construction
$500M+ $100M $50M
From the 2017 BioPhorum Operations Group (BPOG) Technology Roadmap (Page 18, Table 1)
Next Generation Processing
Tough Goals: Reduce Facility Cost and mAb CoGs
New technologies & processing paradigms required6
Facilities are the biggest Cost Driver… but they depend on the Process!
Holistic Approach to Biomanufacturing
7
Total cost of
ownership NPC
(including facility
construction costs,
capital, and operating
costs with
depreciation) for mAb
production at 2000 L
scale with fed-batch
process (3 g/L titer)
▪ Facility cost was 40% of cost of ownership
▪ Implementation of single-use technologies reduced Net Product Cost by 40%
Pralong & Pollard (2017)
Single-Use Technology
Implementation For
Biologics and Vaccines
Production, p.724
Cost drivers in traditional facilities
7
Incentives, Challenges and Pathways
8
Low CoGs needed to
The challenge?
 Supply developing countries with affordable biologics
 Reach emerging markets profitably
 Improve competitiveness and long-term sustainability
 Enable business model for new biologics and novel therapies
(political pressure on pricing, cost is a real factor)
 Great progress in USP (high titer, perfusion reactors)
 DSP still done the traditional way: slow, low yield, large
expensive units
 USP & DSP not integrated
 Facilities are large, expensive, not flexible and long lead
time to construct
Holistic Approach to Biomanufacturing
Better Processes = Smaller Facilities = Lower Costs
Consensus in the Industry?
Next Generation Processing is enabled by High Productivity
9
A High Productivity DSP that matches Intensified USP
10
What is our Proposal?
TRADITIONAL APPROACH
• Resin columns need oversizing to
match USP productivity
 Large footprint, not flexible,
labor/quality-intensive
• High CAPEX & OPEX
 Needs multi-batch amortization
NEW PARADIGM
• High Productivity DSP
• Increased flexibility at lower CapEx
• Cost efficient solution to match high
USP productivity
What is our Proposal?
High Productivity Membrane Chromatography
11
High Productivity
Membrane
Chromatography
• High throughput
achieved without
over-sizing
• Utilization of
rapid multi-
cycling to reduce
media volume
• No amortization
needed
• Single use per batch bind & elute Protein A
• Right-sized flow-through salt-tolerant CEX with HIC modality
• High loading flow-through salt-tolerant AEX
Bioreactor
CEX AEX
Primary
separation
Capture
Intermediate /
polishing
VF UF/DF
Protein AFiltration
Poll 1
The Natrix® Technology
High Productivity Chromatography Membrane
High Binding & Short Residence Time
Natrix® HD membrane
1. Reinforcing mesh “skeleton”
• Provides mechanical strength & durability to composite membrane
• Polypropylene – good chemical stability
2. Porous polymer gel
• 3D macroporous structure provides:
• A large surface area that contains a high density of protein binding groups
• Interconnected pores that provide convective flow channels
14
Natrix® Membranes Flow and Binding Dynamics (1/2)
Combining the best of Resin & Membrane
Natrix® Membranes
o Single use
o Dominated by advective flow
o High binding capacity for
proteins, virus and DNA
o High flow rates
Conventional Column
Chromatography
Natrix® Advective
Chromatography
Resins
o High protein binding capacity
o Limited capacity for large
targets (virus, DNA)
o Diffusional limitations
o Low flow rates
Conventional Membranes
o Single use
o High flow rates
o Limited surface area
o Low binding capacity
Conventional Membrane
Adsorber Chromatography
15
Natrix® Membranes Flow and Binding Dynamics (2/2)
Binding Capacity maintained over wide Residence Time range (1.2s - 12s)
Membrane: maximum 10% loading capacity loss for 10x faster loading
Resin: loading capacity decreased by 80% when residence time decreased by 4x (86s to 21s)
0
20
40
60
80
100
120
0 5 10 15
NormalizedLoadingcapacity%
Residence Time (seconds)
Membrane Resin
Natrix® membranes are flow rate insensitive
Operate at 6s residence time or less with no capacity loss
16
Natrix® Affinity Membranes
Composition & Properties
NatriPur™ HD-A: high productivity Protein A [NOT YET COMMERCIAL]
• Developed for rapid multi-cycling Bind & Elute operation
• Productivity (g mAb/h.L) 30-fold higher than Protein A resins
• Demonstrated for 20+ mAbs
• Single-use per batch
• Caustic stable
• Reactive membrane platform can accommodate multiple types of ligands
• Demonstrated for virus and recombinant proteins purification
17
Natrix® Ion Exchange Membranes
Composition & Properties
NatriPur™ HD-Sb: salt-tolerant CEX with HIC modality [NOT YET COMMERCIAL]
• CEX group – Sulfonic acid
• HIC group – t-Butyl
• High binding capacity and salt tolerance
 Flexible operating conditions
• Caustic stable (1M NaOH)
• Autoclavable
18
Natrix® Ion Exchange Membranes
Composition & Properties
NatriFlo® HD-Q: salt-tolerant AEX [COMMERCIALLY AVAILABLE]
• AEX group – Quaternary amine
• High binding capacity
• Buffers and salt tolerance
 Flexible operating conditions
• Caustic stable (1M NaOH +2M NaCl)
• Autoclavable (Gamma-stable product in development)
19
Poll 2
The Natrix® Paradigm Shift
New template enabled by Natrix®
membrane technologies
Traditional mAb process template
Natrix® Membranes
Towards The New Paradigm
22
Towards The New Paradigm
Natrix® Membranes Unlock A New Way Of Processing: Case Studies
Enabling fully single-use process and true flexible facilities
Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch
Designed for flow-through operation to further increase productivity
Modular and Flexible: can be scaled out rather than scaled up
1
2
3
4
23
Towards The New Paradigm
Natrix® Membranes Unlock A New Way Of Processing: Case Studies
Enabling fully single-use process and true flexible facilities
Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch
Designed for Flow-Through operation to further increase productivity
Modular and Flexible: can be scaled out rather than scaled up
1
2
3
4
24
25
Rethink Protein A
Options exist to replace Protein A…
BUT constraints on process
development time and the
need for a robust
manufacturing are strong
incentives to keep but
rethink Protein A
Enabling Fully Single-Use Processes (1/3)
HCP clearance for Protein A membrane comparable to reference resins
26
Enabling Fully Single-Use Processes (2/3)
27
• NatriPur™ HD-Sb & NatriFlo® HD-Q provide state-of-the-art chromatography performance and are single use
• All other unit operations are already single use
• HD-A Capture is the missing link
• Once implemented: all benefits of flexibility will be unlocked
Enabling Fully Single-Use Processes (3/3)
True fully flexible facilities become reality…
BUT how to handle chromatography cost?
Bioreactor
HD-Sb HD-Q
Primary
separation
Capture
Intermediate /
polishing
VF UF/DF
HD-AFiltration
Towards The New Paradigm
Natrix® Membranes Unlock A New Way Of Processing: Case Studies
Enabling fully single-use process and true fully flexible facilities
Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch
Designed for Flow-Through operation to further increase productivity
Modular and Flexible: can be scaled out rather than scaled up
1
2
3
4
28
Cycling Study mAb 8: 50 cycles @ 20 g/L Load
Avg Leached ProA <2ppm
Avg Delta Column Pressure <2psi
Media life fully utilized within a batch improves economics
29
High Productivity Enables Rapid Multi-Cycling
& Right-Sizing (1/4)
High Productivity Enables Rapid Multi-Cycling
& Right-Sizing (2/4)
30
Up to 5kg mAb produced over 10 days
Perfusion bioreactor
• 100 L
• 2 volumes/day
• Titer: 2.5 g/L
Biosimilar for developing country
• Cost must be low
CV: 23.9L
BC: 35 g/L
CV: 1.2L
BC: 35 g/L
MV: 0.5L
BC: 45 g/L
High flow rate to match
perfusion productivity
BUT too expensive with
long and uncertain
amortization
Expend full life of media/batch
 cost efficient
BUT too slow to match
perfusion rate
Meets perfusion rate with no need to oversize
Rapid Multi-Cycling
• Expend full life of media/batch
 Cost Efficient
Traditional, large column approach
Residence time (sec): 240
Cycle time (min): 180
Hours per day: 3h every 2 days
Cycles over 10 days: 5
Cost-efficient resin column
Residence time (sec): 240
Cycle time (min): 180
Hours per day: 28.4
Cycles over 10 days: 110
Right-sized membrane column
Residence time (sec): 6
Cycle time (min): 12
Hours per day: 4.5
Cycles over 10 days: 200
31
Daily
purification train
matching perfusion
flow rate
MV: 0.5L
Load 45g/L
20 cycles
2.5 hours
95%
yield
90%
yield
98%
yield
HD-Sb
Polish
HD-Q
Polish
HD-A
Capture
MV: 0.5L
Load 300g/L
3 cycles
1.5 hour
MV: 0.03L
Load:12500gg/L
1 cycle
3.5 hours
Adapted from Jacquemart et al., CSBJ, 2016
 4 suites in a 2,000 m2 pod-based micro-facility costing <€20M  500 kg mAb purified annually!
High Productivity Enables Rapid Multi-Cycling
& Right-Sizing (3/4)
CoGs <$50/g compatible with biosimilar markets in developing
countries enabled by right-sizing and rapid multi-cycling
Right-sized high
productivity Protein A
membrane capture
(400 g/h•L-media)
(30X resin productivity)
Straight-Through
Processing in subsequent
high throughput DSP steps
4.5 kg purified for every
batch (10 days) in 20 ft2
of GMP suite.
Benoit Mothes (Sanofi)
 Fully automated, high productivity DSP
 Multi-unit operation system with 3 types of Natrix®
membranes
• Consistent performance (100 cycles) with & without
sanitization every cycle
• Sanitization not required since columns are disposable?
Source: “ASAP: Toward a Fully Disposable Continuous Process”, Mothes et al., BPI
Conference 2014
32
Adrian Gospodarek (MSD)
 First demonstrations of continuous multi-
membrane chromatography
 SMB multi-column system with 5 Natrix® test cells
• 91 cycles
• Load: 30 g/L @ 4 sec RT
• Avg yield: 87%
• Avg HCP reduction: 4.1 LRV
• DNA in eluate: <1 ppm
Source: “High Capacity Protein A Membranes for mAb Capture: An Alternative to
Column Chromatography”, Gospodarek et al., 2016 AIChE Annual Meeting
Continuous purification platforms further optimize productivity
High Productivity Enables Rapid Multi-Cycling
& Right-Sizing (4/4)
Towards The New Paradigm
Natrix® Membranes Unlock A New Way Of Processing: Case Studies
Enabling fully single-use process and true fully flexible facilities
Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch
Designed for Flow-Through operation to further increase productivity
Modular and Flexible: can be scaled out rather than scaled up
1
2
3
4
33
34
Designed for Flow-Through Operation
To further Increase Productivity (1/3)
HCP = 247 ppm
Aggregates = 10.35%
Yield = 93%
HCP = 47 ppm
Aggregates = 0.49%
Yield = 93%
HCP = 3 ppm
Aggregates = 0.42%
NatriPur™
HD-Sb
pH 5.5
10 mS/cm
Load: 300 g/L
NatriFlo®
HD-Q
pH 7.5
2 mS/cm
NatriPur™ HD-Sb:
optimized hold-up volume to
enable multi-cycling mode
(even in FT operations)
NatriFlo® HD-Q:
designed for single cycle,
extended load at high flow
rate and low pressure drop
34
35
Designed for Flow-Through Operation
To further Increase Productivity (2/3)
HCP = 1123 ppm
Aggregates = 1.91%
Yield = 88%
HCP = 162 ppm
Aggregates = 0.75%
Yield = 96%
HCP = 26 ppm
Aggregates = 0.74%
NatriPur™
HD-Sb
pH 7.5
4 mS/cm
Load: 300 g/L
NatriFlo®
HD-Q
pH 7.5
4 mS/cm
2 flow through steps provide further optimization of media utilization and DSP time
 Improved productivity and process economics
No feed adjustment between the flow-through
steps for simple, continuous operation
35
Feed: ProA & CEX Purified mAb
• Titer: 10g/L
• HCP: 70 ppm
Condition: 25mM Tris, pH 7.5, 10ms/cm
NatriFlo® HD-Q FT pool achieves
• HCP <10ppm
• No detectable DNA
• 7 LRV MVM
• Great purification performance at very high loading capacity = Downsize the unit
• Performance maintained at high conductivity = Reduce operations & risks
36
Designed for Flow-Through Operation
To further Increase Productivity (3/3)
Towards The New Paradigm
Natrix® Membranes Unlock A New Way Of Processing: Case Studies
Enabling fully single-use process and true fully flexible facilities
Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch
Designed for Flow-Through operation to further increase productivity
Modular and Flexible: can be scaled out rather than scaled up
1
2
3
4
37
• Combination of multi-cycling and modular units : only the
number of cycles and/or number of columns change
• No technical or regulatory scale up required
• Minimizes investment when risks are high (early phases)
• Maximizes PD efficiency when moving through late stages
• Scaling out enables seamless transition from early stage to
late stage / manufacturing
Modularity Enabled By Productivity38
SCALING OUTSCALING UP
Modular and Flexible
Can be Scaled Out rather than Scaled Up (1/2)
39
800
32
Phase 1
Batch size (g)
# of cycles
Batch processing
time (hrs)
Phase 2 Phase 3 Commercial
No change in unit operation: no process development or regulatory work
From bench to bedside: one size fits all!
2000
80
4000
80
8000
80
80
80
80
80
Modular and Flexible
Can be Scaled Out rather than Scaled Up (2/2)
2 4.9 5 5.1
Poll 3
Conclusions
Cost savings are confirmed even for large scale manufacturing
42
Reproduced from Pollard et al.,
BPI, 2016
The BioSolve® model developed by MSD supports earlier conclusions
Natrix® High Productivity Membrane Chromatography
Enabling the Next Generation Bioprocessing Paradigm
1 Critical quality attributes comparable to reference resin
processes
2
Single use, high productivity chromatography enables
• Fully single-use, modular processes
• Unlocking true flexible facilities that promote better facility utilization
• Rapid multi-cycling, right-sizing, full utilization of media life in 1 batch
3 Cost-efficiency is achievable for both clinical and
commercial manufacturing by realizing a holistic strategy
43
New paradigm enabled by Natrix®
membrane technologies
Traditional mab process template
The future
The vibrant M, Natrix, NatriPur, and NatriFlo are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their
respective owners. Detailed information on trademarks is available via publicly accessible resources.
© 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
Renaud Jacquemart, Ph.D.
Director, Vaccines Process Sciences
Natrix Separations, Inc.
5295 John Lucas Drive – Unit 6
Burlington, ON Canada L7L6A8
renaud@natrixseparations.com
Cell: 289-828-0728

More Related Content

PDF
Complete single-use ADC technology from development through scale-up
PDF
Driving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
PDF
Process Intensification for future bioprocessing
PDF
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
PDF
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
PPTX
Process Development for Cell Therapy and Viral Gene Therapy
PDF
Get Proactive With Your Stability Program
PDF
Key Considerations & Case Study for Building a cGMP Biomanufacturing Facility
Complete single-use ADC technology from development through scale-up
Driving Value in the Evolution Toward Continuous Monoclonal Antibody Processing
Process Intensification for future bioprocessing
Employing Innovative Platform Manufacturing and Biosafety Testing for your Ge...
A Cost Analysis and Evaluation of Perfused Seed Train Scenarios Through Proce...
Process Development for Cell Therapy and Viral Gene Therapy
Get Proactive With Your Stability Program
Key Considerations & Case Study for Building a cGMP Biomanufacturing Facility

What's hot (16)

PDF
Membrane Chromatography Solutions for Single-Use, Intensified mAb Purification
PDF
How to reach High Plasma Protein Concentration with Single-Pass TFF
PDF
Investing in Process Development for Increased MSC Production in Stirred Tank...
PDF
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
PDF
Webinar: A Scale-up to 2000L, Blindfolded!
PDF
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
PDF
Webinar: Novel Perfusion Filter and Controller for N-1 Application
PDF
Accelerate Delivery of High Producing Cell Lines
PDF
Accelerating cell therapy manufacturing through robust process development - ...
PDF
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
PPTX
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
PDF
Addressing the Challenge of Scalability in Viral Vectors
PPT
Custom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
PPTX
Webinar: Benefits of Monodisperse Activated PEGs in ADC Development
PDF
Hot melt extrusion with PVA: A new opportunity for challenging APIs
PDF
Media and Process Development for Seed Train Intensification
Membrane Chromatography Solutions for Single-Use, Intensified mAb Purification
How to reach High Plasma Protein Concentration with Single-Pass TFF
Investing in Process Development for Increased MSC Production in Stirred Tank...
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell...
Webinar: A Scale-up to 2000L, Blindfolded!
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Accelerate Delivery of High Producing Cell Lines
Accelerating cell therapy manufacturing through robust process development - ...
Scaling Strategies with Stirred Single-Use Bioreactors from Bench to Clinical...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Addressing the Challenge of Scalability in Viral Vectors
Custom Affinity Chromatography for Vaccine Purification: A New PD Paradigm
Webinar: Benefits of Monodisperse Activated PEGs in ADC Development
Hot melt extrusion with PVA: A new opportunity for challenging APIs
Media and Process Development for Seed Train Intensification
Ad

Similar to High Productivity Membrane Chromatography: Enabling the Next Generation Bioprocessing Paradigm (20)

PDF
Membrane Chromatography Solutions for Single-Use, Intensified mAb Purification
PDF
Webinar: Novel Perfusion Filter and Controller for N-1 Application
PDF
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
PDF
Puridify's Presentation
PDF
The Biocontinuum™ Seed Train Platform
PDF
The Biocontinuum™ Seed Train Platform
PDF
A Novel Approach to Diafiltration for Intensified or Continuous Processing
PDF
Process Development for Continuous Flow-Through Polishing Purification for mA...
PDF
Process Development for Continuous Flow-Through Polishing Purification for mA...
PDF
Pesquisas recentes de fibras recicladas tissue
PDF
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
PDF
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
PPTX
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
PPTX
Spectacular Success of PMP Intelli-Tissue® 1200 EcoEc Crescent Former Tissue ...
PDF
Tackling the challenges of single-use manufacturing for ADCs
PDF
Tackling the challenges of single-use manufacturing for ADCs
PDF
UPM Malaysia advanced material technology
PDF
Páginas desdeAn Efficient and cGMP.pdf
PDF
Find your filter. What’s best for your process?
PDF
Find your filter. What’s best for your process?
Membrane Chromatography Solutions for Single-Use, Intensified mAb Purification
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Handling High Titer Processes and Strategies for DSP Facility Fit | KBI Biop...
Puridify's Presentation
The Biocontinuum™ Seed Train Platform
The Biocontinuum™ Seed Train Platform
A Novel Approach to Diafiltration for Intensified or Continuous Processing
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
Pesquisas recentes de fibras recicladas tissue
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Spectacular Success of PMP Intelli-Tissue® 1200 EcoEc Crescent Former Tissue ...
Tackling the challenges of single-use manufacturing for ADCs
Tackling the challenges of single-use manufacturing for ADCs
UPM Malaysia advanced material technology
Páginas desdeAn Efficient and cGMP.pdf
Find your filter. What’s best for your process?
Find your filter. What’s best for your process?
Ad

More from MilliporeSigma (20)

PDF
Launch of our new Titanium Dioxide Alternative
PDF
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
PDF
Use of Excipients in Downstream Processing to Improve Protein Purification
PDF
Exploring the protein stabilizing capability of surfactants against agitation...
PDF
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
PDF
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
PDF
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
PDF
The Future of Pharma- and Biopharmaceutical Audits
PDF
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
PDF
Identity testing by NGS as a means of risk mitigation for viral gene therapies
PDF
Latest advancements of melt based 3D printing technologies for oral drug deli...
PDF
How does the ICH Q5A revision impact viral safety strategies for biologics?
PDF
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
PDF
Insights from a Global Collaboration Accelerating Vaccine Development with an...
PDF
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
PDF
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
PDF
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
PDF
The Developability Classification System (DCS): Enabling an Optimized Approac...
PDF
How to Accelerate and Enhance ADC Therapies
PDF
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...
Launch of our new Titanium Dioxide Alternative
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
Use of Excipients in Downstream Processing to Improve Protein Purification
Exploring the protein stabilizing capability of surfactants against agitation...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Future of Pharma- and Biopharmaceutical Audits
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Latest advancements of melt based 3D printing technologies for oral drug deli...
How does the ICH Q5A revision impact viral safety strategies for biologics?
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The Developability Classification System (DCS): Enabling an Optimized Approac...
How to Accelerate and Enhance ADC Therapies
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...

Recently uploaded (20)

PPTX
1. Drug Distribution System.pptt b pharmacy
PPTX
community services team project 2(4).pptx
PDF
Khaled Sary- Trailblazers of Transformation Middle East's 5 Most Inspiring Le...
PPTX
COMMUNICATION SKILSS IN NURSING PRACTICE
PPTX
Pulmonary Circulation PPT final for easy
PPTX
HEMODYNAMICS - I DERANGEMENTS OF BODY FLUIDS.pptx
PPT
Recent advances in Diagnosis of Autoimmune Disorders
PPTX
PEDIATRIC OSCE, MBBS, by Dr. Sangit Chhantyal(IOM)..pptx
PPTX
AI_in_Pharmaceutical_Technology_Presentation.pptx
PDF
MECE & SCQA FRAMEWORKS, - Adding Innovation & Influencing Hospital & Super-Sp...
PPTX
BLS, BCLS Module-A life saving procedure
PPTX
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...
PPT
Parental-Carer-mental-illness-and-Potential-impact-on-Dependant-Children.ppt
PDF
Dermatology diseases Index August 2025.pdf
PPTX
Medical aspects of impairment including all the domains mentioned in ICF
PPTX
Infection prevention and control for medical students
PDF
Pharmacology slides archer and nclex quest
PDF
DAY-6. Summer class. Ppt. Cultural Nursing
PDF
NUTRITION THROUGHOUT THE LIFE CYCLE CHILDHOOD -AGEING
PPTX
First aid in common emergency conditions.pptx
1. Drug Distribution System.pptt b pharmacy
community services team project 2(4).pptx
Khaled Sary- Trailblazers of Transformation Middle East's 5 Most Inspiring Le...
COMMUNICATION SKILSS IN NURSING PRACTICE
Pulmonary Circulation PPT final for easy
HEMODYNAMICS - I DERANGEMENTS OF BODY FLUIDS.pptx
Recent advances in Diagnosis of Autoimmune Disorders
PEDIATRIC OSCE, MBBS, by Dr. Sangit Chhantyal(IOM)..pptx
AI_in_Pharmaceutical_Technology_Presentation.pptx
MECE & SCQA FRAMEWORKS, - Adding Innovation & Influencing Hospital & Super-Sp...
BLS, BCLS Module-A life saving procedure
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...
Parental-Carer-mental-illness-and-Potential-impact-on-Dependant-Children.ppt
Dermatology diseases Index August 2025.pdf
Medical aspects of impairment including all the domains mentioned in ICF
Infection prevention and control for medical students
Pharmacology slides archer and nclex quest
DAY-6. Summer class. Ppt. Cultural Nursing
NUTRITION THROUGHOUT THE LIFE CYCLE CHILDHOOD -AGEING
First aid in common emergency conditions.pptx

High Productivity Membrane Chromatography: Enabling the Next Generation Bioprocessing Paradigm

  • 1. Merck KGaA Darmstadt, Germany Renaud Jacquemart, Ph.D. Principal Scientist Director Vaccines Process Sciences Enabling the next generation bioprocessing paradigm High productivity membrane chromatography
  • 2. 2 The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
  • 4. Next Generation Processing Any technology, expendable, service, or system which significantly changes the existing monoclonal antibody manufacturing template to deliver: Speed Flexibility Quality Cost4
  • 5. Performance Drivers Flexibility Reduce product change- over time by 90% Speed Reduce facility construction, mAb production and product release times Cost 90% reduction in cost to manufacture and capital expenditure Quality Increased robustness and reliability BioPhorum Operations Group (BPOG) Technology Roadmap The Industry Requires Step Change in Performance Process Analytics Process Intensification Single Use Enablers 5
  • 6. Driver Metric Current State 5-yr target 10-yr target Flexibility Facility utilization <70% >85% >95% Product changeover time 3 days <18 hours <8 hours Time to reconfigure suite for new process >2 weeks <1 week <2 days Speed Facility build speed 3 years 2 years 1 year Time to make product 4-6 months 2 months 1 month Quality Cost of quality >10% of operating cost 10% of operating cost 2% of operating cost Inventory cover 3-6 months 2 months 2 weeks Cost Total cost to supply $100/g $50/g $10/g Cost of facility construction $500M+ $100M $50M From the 2017 BioPhorum Operations Group (BPOG) Technology Roadmap (Page 18, Table 1) Next Generation Processing Tough Goals: Reduce Facility Cost and mAb CoGs New technologies & processing paradigms required6
  • 7. Facilities are the biggest Cost Driver… but they depend on the Process! Holistic Approach to Biomanufacturing 7 Total cost of ownership NPC (including facility construction costs, capital, and operating costs with depreciation) for mAb production at 2000 L scale with fed-batch process (3 g/L titer) ▪ Facility cost was 40% of cost of ownership ▪ Implementation of single-use technologies reduced Net Product Cost by 40% Pralong & Pollard (2017) Single-Use Technology Implementation For Biologics and Vaccines Production, p.724 Cost drivers in traditional facilities 7
  • 8. Incentives, Challenges and Pathways 8 Low CoGs needed to The challenge?  Supply developing countries with affordable biologics  Reach emerging markets profitably  Improve competitiveness and long-term sustainability  Enable business model for new biologics and novel therapies (political pressure on pricing, cost is a real factor)  Great progress in USP (high titer, perfusion reactors)  DSP still done the traditional way: slow, low yield, large expensive units  USP & DSP not integrated  Facilities are large, expensive, not flexible and long lead time to construct Holistic Approach to Biomanufacturing Better Processes = Smaller Facilities = Lower Costs
  • 9. Consensus in the Industry? Next Generation Processing is enabled by High Productivity 9
  • 10. A High Productivity DSP that matches Intensified USP 10 What is our Proposal? TRADITIONAL APPROACH • Resin columns need oversizing to match USP productivity  Large footprint, not flexible, labor/quality-intensive • High CAPEX & OPEX  Needs multi-batch amortization NEW PARADIGM • High Productivity DSP • Increased flexibility at lower CapEx • Cost efficient solution to match high USP productivity
  • 11. What is our Proposal? High Productivity Membrane Chromatography 11 High Productivity Membrane Chromatography • High throughput achieved without over-sizing • Utilization of rapid multi- cycling to reduce media volume • No amortization needed • Single use per batch bind & elute Protein A • Right-sized flow-through salt-tolerant CEX with HIC modality • High loading flow-through salt-tolerant AEX Bioreactor CEX AEX Primary separation Capture Intermediate / polishing VF UF/DF Protein AFiltration
  • 14. High Productivity Chromatography Membrane High Binding & Short Residence Time Natrix® HD membrane 1. Reinforcing mesh “skeleton” • Provides mechanical strength & durability to composite membrane • Polypropylene – good chemical stability 2. Porous polymer gel • 3D macroporous structure provides: • A large surface area that contains a high density of protein binding groups • Interconnected pores that provide convective flow channels 14
  • 15. Natrix® Membranes Flow and Binding Dynamics (1/2) Combining the best of Resin & Membrane Natrix® Membranes o Single use o Dominated by advective flow o High binding capacity for proteins, virus and DNA o High flow rates Conventional Column Chromatography Natrix® Advective Chromatography Resins o High protein binding capacity o Limited capacity for large targets (virus, DNA) o Diffusional limitations o Low flow rates Conventional Membranes o Single use o High flow rates o Limited surface area o Low binding capacity Conventional Membrane Adsorber Chromatography 15
  • 16. Natrix® Membranes Flow and Binding Dynamics (2/2) Binding Capacity maintained over wide Residence Time range (1.2s - 12s) Membrane: maximum 10% loading capacity loss for 10x faster loading Resin: loading capacity decreased by 80% when residence time decreased by 4x (86s to 21s) 0 20 40 60 80 100 120 0 5 10 15 NormalizedLoadingcapacity% Residence Time (seconds) Membrane Resin Natrix® membranes are flow rate insensitive Operate at 6s residence time or less with no capacity loss 16
  • 17. Natrix® Affinity Membranes Composition & Properties NatriPur™ HD-A: high productivity Protein A [NOT YET COMMERCIAL] • Developed for rapid multi-cycling Bind & Elute operation • Productivity (g mAb/h.L) 30-fold higher than Protein A resins • Demonstrated for 20+ mAbs • Single-use per batch • Caustic stable • Reactive membrane platform can accommodate multiple types of ligands • Demonstrated for virus and recombinant proteins purification 17
  • 18. Natrix® Ion Exchange Membranes Composition & Properties NatriPur™ HD-Sb: salt-tolerant CEX with HIC modality [NOT YET COMMERCIAL] • CEX group – Sulfonic acid • HIC group – t-Butyl • High binding capacity and salt tolerance  Flexible operating conditions • Caustic stable (1M NaOH) • Autoclavable 18
  • 19. Natrix® Ion Exchange Membranes Composition & Properties NatriFlo® HD-Q: salt-tolerant AEX [COMMERCIALLY AVAILABLE] • AEX group – Quaternary amine • High binding capacity • Buffers and salt tolerance  Flexible operating conditions • Caustic stable (1M NaOH +2M NaCl) • Autoclavable (Gamma-stable product in development) 19
  • 22. New template enabled by Natrix® membrane technologies Traditional mAb process template Natrix® Membranes Towards The New Paradigm 22
  • 23. Towards The New Paradigm Natrix® Membranes Unlock A New Way Of Processing: Case Studies Enabling fully single-use process and true flexible facilities Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch Designed for flow-through operation to further increase productivity Modular and Flexible: can be scaled out rather than scaled up 1 2 3 4 23
  • 24. Towards The New Paradigm Natrix® Membranes Unlock A New Way Of Processing: Case Studies Enabling fully single-use process and true flexible facilities Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch Designed for Flow-Through operation to further increase productivity Modular and Flexible: can be scaled out rather than scaled up 1 2 3 4 24
  • 25. 25 Rethink Protein A Options exist to replace Protein A… BUT constraints on process development time and the need for a robust manufacturing are strong incentives to keep but rethink Protein A Enabling Fully Single-Use Processes (1/3)
  • 26. HCP clearance for Protein A membrane comparable to reference resins 26 Enabling Fully Single-Use Processes (2/3)
  • 27. 27 • NatriPur™ HD-Sb & NatriFlo® HD-Q provide state-of-the-art chromatography performance and are single use • All other unit operations are already single use • HD-A Capture is the missing link • Once implemented: all benefits of flexibility will be unlocked Enabling Fully Single-Use Processes (3/3) True fully flexible facilities become reality… BUT how to handle chromatography cost? Bioreactor HD-Sb HD-Q Primary separation Capture Intermediate / polishing VF UF/DF HD-AFiltration
  • 28. Towards The New Paradigm Natrix® Membranes Unlock A New Way Of Processing: Case Studies Enabling fully single-use process and true fully flexible facilities Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch Designed for Flow-Through operation to further increase productivity Modular and Flexible: can be scaled out rather than scaled up 1 2 3 4 28
  • 29. Cycling Study mAb 8: 50 cycles @ 20 g/L Load Avg Leached ProA <2ppm Avg Delta Column Pressure <2psi Media life fully utilized within a batch improves economics 29 High Productivity Enables Rapid Multi-Cycling & Right-Sizing (1/4)
  • 30. High Productivity Enables Rapid Multi-Cycling & Right-Sizing (2/4) 30 Up to 5kg mAb produced over 10 days Perfusion bioreactor • 100 L • 2 volumes/day • Titer: 2.5 g/L Biosimilar for developing country • Cost must be low CV: 23.9L BC: 35 g/L CV: 1.2L BC: 35 g/L MV: 0.5L BC: 45 g/L High flow rate to match perfusion productivity BUT too expensive with long and uncertain amortization Expend full life of media/batch  cost efficient BUT too slow to match perfusion rate Meets perfusion rate with no need to oversize Rapid Multi-Cycling • Expend full life of media/batch  Cost Efficient Traditional, large column approach Residence time (sec): 240 Cycle time (min): 180 Hours per day: 3h every 2 days Cycles over 10 days: 5 Cost-efficient resin column Residence time (sec): 240 Cycle time (min): 180 Hours per day: 28.4 Cycles over 10 days: 110 Right-sized membrane column Residence time (sec): 6 Cycle time (min): 12 Hours per day: 4.5 Cycles over 10 days: 200
  • 31. 31 Daily purification train matching perfusion flow rate MV: 0.5L Load 45g/L 20 cycles 2.5 hours 95% yield 90% yield 98% yield HD-Sb Polish HD-Q Polish HD-A Capture MV: 0.5L Load 300g/L 3 cycles 1.5 hour MV: 0.03L Load:12500gg/L 1 cycle 3.5 hours Adapted from Jacquemart et al., CSBJ, 2016  4 suites in a 2,000 m2 pod-based micro-facility costing <€20M  500 kg mAb purified annually! High Productivity Enables Rapid Multi-Cycling & Right-Sizing (3/4) CoGs <$50/g compatible with biosimilar markets in developing countries enabled by right-sizing and rapid multi-cycling Right-sized high productivity Protein A membrane capture (400 g/h•L-media) (30X resin productivity) Straight-Through Processing in subsequent high throughput DSP steps 4.5 kg purified for every batch (10 days) in 20 ft2 of GMP suite.
  • 32. Benoit Mothes (Sanofi)  Fully automated, high productivity DSP  Multi-unit operation system with 3 types of Natrix® membranes • Consistent performance (100 cycles) with & without sanitization every cycle • Sanitization not required since columns are disposable? Source: “ASAP: Toward a Fully Disposable Continuous Process”, Mothes et al., BPI Conference 2014 32 Adrian Gospodarek (MSD)  First demonstrations of continuous multi- membrane chromatography  SMB multi-column system with 5 Natrix® test cells • 91 cycles • Load: 30 g/L @ 4 sec RT • Avg yield: 87% • Avg HCP reduction: 4.1 LRV • DNA in eluate: <1 ppm Source: “High Capacity Protein A Membranes for mAb Capture: An Alternative to Column Chromatography”, Gospodarek et al., 2016 AIChE Annual Meeting Continuous purification platforms further optimize productivity High Productivity Enables Rapid Multi-Cycling & Right-Sizing (4/4)
  • 33. Towards The New Paradigm Natrix® Membranes Unlock A New Way Of Processing: Case Studies Enabling fully single-use process and true fully flexible facilities Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch Designed for Flow-Through operation to further increase productivity Modular and Flexible: can be scaled out rather than scaled up 1 2 3 4 33
  • 34. 34 Designed for Flow-Through Operation To further Increase Productivity (1/3) HCP = 247 ppm Aggregates = 10.35% Yield = 93% HCP = 47 ppm Aggregates = 0.49% Yield = 93% HCP = 3 ppm Aggregates = 0.42% NatriPur™ HD-Sb pH 5.5 10 mS/cm Load: 300 g/L NatriFlo® HD-Q pH 7.5 2 mS/cm NatriPur™ HD-Sb: optimized hold-up volume to enable multi-cycling mode (even in FT operations) NatriFlo® HD-Q: designed for single cycle, extended load at high flow rate and low pressure drop 34
  • 35. 35 Designed for Flow-Through Operation To further Increase Productivity (2/3) HCP = 1123 ppm Aggregates = 1.91% Yield = 88% HCP = 162 ppm Aggregates = 0.75% Yield = 96% HCP = 26 ppm Aggregates = 0.74% NatriPur™ HD-Sb pH 7.5 4 mS/cm Load: 300 g/L NatriFlo® HD-Q pH 7.5 4 mS/cm 2 flow through steps provide further optimization of media utilization and DSP time  Improved productivity and process economics No feed adjustment between the flow-through steps for simple, continuous operation 35
  • 36. Feed: ProA & CEX Purified mAb • Titer: 10g/L • HCP: 70 ppm Condition: 25mM Tris, pH 7.5, 10ms/cm NatriFlo® HD-Q FT pool achieves • HCP <10ppm • No detectable DNA • 7 LRV MVM • Great purification performance at very high loading capacity = Downsize the unit • Performance maintained at high conductivity = Reduce operations & risks 36 Designed for Flow-Through Operation To further Increase Productivity (3/3)
  • 37. Towards The New Paradigm Natrix® Membranes Unlock A New Way Of Processing: Case Studies Enabling fully single-use process and true fully flexible facilities Rapid multi-cycling, right-sizing and full utilization of media life in 1 batch Designed for Flow-Through operation to further increase productivity Modular and Flexible: can be scaled out rather than scaled up 1 2 3 4 37
  • 38. • Combination of multi-cycling and modular units : only the number of cycles and/or number of columns change • No technical or regulatory scale up required • Minimizes investment when risks are high (early phases) • Maximizes PD efficiency when moving through late stages • Scaling out enables seamless transition from early stage to late stage / manufacturing Modularity Enabled By Productivity38 SCALING OUTSCALING UP Modular and Flexible Can be Scaled Out rather than Scaled Up (1/2)
  • 39. 39 800 32 Phase 1 Batch size (g) # of cycles Batch processing time (hrs) Phase 2 Phase 3 Commercial No change in unit operation: no process development or regulatory work From bench to bedside: one size fits all! 2000 80 4000 80 8000 80 80 80 80 80 Modular and Flexible Can be Scaled Out rather than Scaled Up (2/2) 2 4.9 5 5.1
  • 42. Cost savings are confirmed even for large scale manufacturing 42 Reproduced from Pollard et al., BPI, 2016 The BioSolve® model developed by MSD supports earlier conclusions
  • 43. Natrix® High Productivity Membrane Chromatography Enabling the Next Generation Bioprocessing Paradigm 1 Critical quality attributes comparable to reference resin processes 2 Single use, high productivity chromatography enables • Fully single-use, modular processes • Unlocking true flexible facilities that promote better facility utilization • Rapid multi-cycling, right-sizing, full utilization of media life in 1 batch 3 Cost-efficiency is achievable for both clinical and commercial manufacturing by realizing a holistic strategy 43
  • 44. New paradigm enabled by Natrix® membrane technologies Traditional mab process template The future
  • 45. The vibrant M, Natrix, NatriPur, and NatriFlo are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. © 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Renaud Jacquemart, Ph.D. Director, Vaccines Process Sciences Natrix Separations, Inc. 5295 John Lucas Drive – Unit 6 Burlington, ON Canada L7L6A8 renaud@natrixseparations.com Cell: 289-828-0728